In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
|Articles|August 19, 2013
Fertility-Preservation Education Program at MSKCC Boosts Nurse Discussion of Options, Referrals
At ONS Congress 2013, Rebekah Clark discusses a standardized fertility-preservation education program that boosted nurse-patient discussion of fertility options from 0 to 71% and referrals for interested patients from 17% to 80% (abstract 95960).
Advertisement
At ONS Congress 2013, Rebekah Clark discusses a standardized fertility-preservation education program that boosted nurse-patient discussion of fertility options from 0 to 71% and referrals for interested patients from 17% to 80% (abstract 95960).
Advertisement
Related to this article
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
Matthew Lee, MD, discusses the first clinical data for BG-C477, a CEACAM5-targeting ADC, in advanced NSCLC.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in nonpalpable breast cancer.
ASCENT-03 subgroup data show sacituzumab govitecan improved PFS vs chemotherapy across subgroups in untreated metastatic TNBC.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Bispecific antibodies targeting PD-L1 showed activity across first-, second-, and later-line advanced neuroendocrine carcinoma in 3 trials presented at ESMO 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
2
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
3
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
4
What Are the Top Takeaways for Neuroendocrine Carcinoma From 2026 ESMO?
5